These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11902060)

  • 1. The biological and economic value of oral organic iron in maintenance dialysis.
    Wish JB; Fourtner P; Ghaddar S; Moore GM
    Nephrol News Issues; 2002 Mar; 16(4):32-3, 37-9. PubMed ID: 11902060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing an i.v. iron maintenance regimen protocol in a hemodialysis practice.
    Gilmartin C; Na-Thalang K; Arruda J; Lau A
    Nephrol Nurs J; 2004; 31(6):663-71. PubMed ID: 15686330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic considerations in a changing anemia environment.
    Pizzi LT
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they?
    Steinman TI; Nissenson AR; Glassock RJ; Dickmeyer J; Mattern WD; Parker TF; Hull AR
    Nephrol News Issues; 2003 Apr; 17(5):28-30, 32-4, 36 passim. PubMed ID: 12715624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosing and treating anemia and iron deficiency in hemodialysis patients.
    Foret JP
    Nephrol Nurs J; 2002 Jun; 29(3):292-6. PubMed ID: 12164080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
    J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
    Deaver K; Bennington L
    Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
    Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
    J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of end-stage renal disease care in South Asia.
    Jha V
    Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients?
    Garneata L
    J Ren Nutr; 2008 Jan; 18(1):40-5. PubMed ID: 18089442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Past, present, and future of chronic kidney disease anemia management in the United States.
    Wish JB
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):101-8. PubMed ID: 19233069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
    Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
    Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of management and treatment responses in haemodialysis patients from Tehran province, Iran.
    Mahdavi-Mazdeh M; Zamyadi M; Nafar M
    Nephrol Dial Transplant; 2008 Jan; 23(1):288-93. PubMed ID: 17965435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron administration during the maintenance period in erythropoietin-treated hemodialysis patients: a simple and effective method.
    Nurnuansuwan S; Leelahavanichkul A; Pansin P; Eiam-Ong S
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S184-8. PubMed ID: 16623026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous iron supplementation in children on hemodialysis.
    Leijn E; Monnens LA; Cornelissen EA
    J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Principles of iron therapy in hemodialysis patients].
    Basić-Jukić N; Kes P; Jurić I
    Acta Med Croatica; 2006 Dec; 60(5):457-62. PubMed ID: 17217102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.